SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) May 17, 1996
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification no.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) ( Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On May 17, 1996 Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that it continues to see
significant progress in the patient testing of the
production model of the Diasensor 1000 noninvasive
glucose sensor for diabetics.
At the Indiana, PA calibration center, patients
are being tested with the sensor to gather data on this
production model for submission of the revised 510(k)
notification of the Food and Drug Administration (FDA).
Based on the data gathered thus far, the Diasensor 1000
is performing much better than the research model on
which the original 510(k) notification data was based.
The Company further stated, in response to recent
press, that the Company believes there is no basis for the
proposed Class Action lawsuits recently filed, one by a
plaintiff who reportedly purchased less than 2,000 shares of
common stock.
The first suit has been reviewed by both the
company's litigation and securities counsel, and both firms
agree that a Rule 12(b)(6) Motion to Dismiss is appropriate.
As part of its defense, the Company intends to rely on the new
federal Securities Litigation Reform Act which was passed in
December of 1995 to eliminate abusive and meritless suits.
The Company intends to fight vigorously against this action,
two others filed recently, and any other actions that may be
pursued.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - News Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: May 17, 1996
